Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
EDG-5506 is an orally administered investigational therapy small molecule, targets fast skeletal myosin to protect dystrophic muscle and reduce muscle damage biomarkers in a Phase 1 trial in becker muscular dystrophy and duchenne muscular dystrophy.
Lead Product(s): Sevasemten
Therapeutic Area: Genetic Disease Product Name: EDG-5506
Highest Development Status: Phase IProduct Type: Small molecule
Recipient: Edgewise Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 08, 2022